Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG br0131

Michael A. Vogelbaum, Brian Berkey, David Peereboom, David Macdonald, Caterina Giannini, John H. Suh, Robert Jenkins, James Herman, Paul Brown, Deborah T. Blumenthal, Christopher Biggs, Christopher Schultz, Minesh Mehta

Research output: Contribution to journalArticle

Abstract

The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA). Preirradiation temozolomide (150 mg/m2/day) was given on a 7-day-on/7-day-off schedule for up to six cycles. The primary end point was the response rate during the 6-month, pre-RT chemotherapy. Tumor tissue was analyzed for the presence of chromosomal deletions on 1p and 19q and for MGMT-promoter methylation. Forty-two patients were enrolled; 39 were eligible. The objective response rate was 32% (6% [complete response, CR], 26% [partial response PR]), and the rate of progression during pre-RT chemotherapy was 10%. The worst nonhematological toxicity was grade 4 in three patients (8%). Twenty-two patients completed concurrent chemotherapy and RT. There were no grade 4 nonhematological toxicities during the concurrent chemotherapy and RT. Seventeen of 28 (60.7%) evaluable cases had codeletion of 1p/19q; all 17 were free from progression at 6 months. Sixteen of 20 (80%) evaluable cases had MGMT-promoter methylation; all 16 were free from progression at 6 months. In conclusion, the rate of progression of 10% during pre-RT temozolomide chemotherapy for newly diagnosed AO and MAO compared favorably with prior experience with pre-RT PCV chemotherapy (20% in RTOG 9402). The toxicity of the dose-intense pre-RT regimen used in this study may warrant evaluation of other, less intense dosing strategies. Future studies will need to prospectively stratify patients according to the presence of deletions of chromosomes 1p and 19q. Neuro-Oncology 11, 167-175, 2009 (Posted to Neuro- Oncology [serial online], Doc. D08-00104, September 8, 2008. URL http://neuro-oncology.dukejournals.org;

Original languageEnglish (US)
Pages (from-to)167-175
Number of pages9
JournalNeuro-Oncology
Volume11
Issue number2
DOIs
StatePublished - Apr 2009

Fingerprint

temozolomide
Oligodendroglioma
Astrocytoma
Radiotherapy
Drug Therapy
Methylation
Monoamine Oxidase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas : RTOG br0131. / Vogelbaum, Michael A.; Berkey, Brian; Peereboom, David; Macdonald, David; Giannini, Caterina; Suh, John H.; Jenkins, Robert; Herman, James; Brown, Paul; Blumenthal, Deborah T.; Biggs, Christopher; Schultz, Christopher; Mehta, Minesh.

In: Neuro-Oncology, Vol. 11, No. 2, 04.2009, p. 167-175.

Research output: Contribution to journalArticle

Vogelbaum, MA, Berkey, B, Peereboom, D, Macdonald, D, Giannini, C, Suh, JH, Jenkins, R, Herman, J, Brown, P, Blumenthal, DT, Biggs, C, Schultz, C & Mehta, M 2009, 'Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG br0131', Neuro-Oncology, vol. 11, no. 2, pp. 167-175. https://doi.org/10.1215/15228517-2008-073
Vogelbaum, Michael A. ; Berkey, Brian ; Peereboom, David ; Macdonald, David ; Giannini, Caterina ; Suh, John H. ; Jenkins, Robert ; Herman, James ; Brown, Paul ; Blumenthal, Deborah T. ; Biggs, Christopher ; Schultz, Christopher ; Mehta, Minesh. / Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas : RTOG br0131. In: Neuro-Oncology. 2009 ; Vol. 11, No. 2. pp. 167-175.
@article{b15763d51953452caffdb476511c42d6,
title = "Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG br0131",
abstract = "The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA). Preirradiation temozolomide (150 mg/m2/day) was given on a 7-day-on/7-day-off schedule for up to six cycles. The primary end point was the response rate during the 6-month, pre-RT chemotherapy. Tumor tissue was analyzed for the presence of chromosomal deletions on 1p and 19q and for MGMT-promoter methylation. Forty-two patients were enrolled; 39 were eligible. The objective response rate was 32{\%} (6{\%} [complete response, CR], 26{\%} [partial response PR]), and the rate of progression during pre-RT chemotherapy was 10{\%}. The worst nonhematological toxicity was grade 4 in three patients (8{\%}). Twenty-two patients completed concurrent chemotherapy and RT. There were no grade 4 nonhematological toxicities during the concurrent chemotherapy and RT. Seventeen of 28 (60.7{\%}) evaluable cases had codeletion of 1p/19q; all 17 were free from progression at 6 months. Sixteen of 20 (80{\%}) evaluable cases had MGMT-promoter methylation; all 16 were free from progression at 6 months. In conclusion, the rate of progression of 10{\%} during pre-RT temozolomide chemotherapy for newly diagnosed AO and MAO compared favorably with prior experience with pre-RT PCV chemotherapy (20{\%} in RTOG 9402). The toxicity of the dose-intense pre-RT regimen used in this study may warrant evaluation of other, less intense dosing strategies. Future studies will need to prospectively stratify patients according to the presence of deletions of chromosomes 1p and 19q. Neuro-Oncology 11, 167-175, 2009 (Posted to Neuro- Oncology [serial online], Doc. D08-00104, September 8, 2008. URL http://neuro-oncology.dukejournals.org;",
author = "Vogelbaum, {Michael A.} and Brian Berkey and David Peereboom and David Macdonald and Caterina Giannini and Suh, {John H.} and Robert Jenkins and James Herman and Paul Brown and Blumenthal, {Deborah T.} and Christopher Biggs and Christopher Schultz and Minesh Mehta",
year = "2009",
month = "4",
doi = "10.1215/15228517-2008-073",
language = "English (US)",
volume = "11",
pages = "167--175",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas

T2 - RTOG br0131

AU - Vogelbaum, Michael A.

AU - Berkey, Brian

AU - Peereboom, David

AU - Macdonald, David

AU - Giannini, Caterina

AU - Suh, John H.

AU - Jenkins, Robert

AU - Herman, James

AU - Brown, Paul

AU - Blumenthal, Deborah T.

AU - Biggs, Christopher

AU - Schultz, Christopher

AU - Mehta, Minesh

PY - 2009/4

Y1 - 2009/4

N2 - The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA). Preirradiation temozolomide (150 mg/m2/day) was given on a 7-day-on/7-day-off schedule for up to six cycles. The primary end point was the response rate during the 6-month, pre-RT chemotherapy. Tumor tissue was analyzed for the presence of chromosomal deletions on 1p and 19q and for MGMT-promoter methylation. Forty-two patients were enrolled; 39 were eligible. The objective response rate was 32% (6% [complete response, CR], 26% [partial response PR]), and the rate of progression during pre-RT chemotherapy was 10%. The worst nonhematological toxicity was grade 4 in three patients (8%). Twenty-two patients completed concurrent chemotherapy and RT. There were no grade 4 nonhematological toxicities during the concurrent chemotherapy and RT. Seventeen of 28 (60.7%) evaluable cases had codeletion of 1p/19q; all 17 were free from progression at 6 months. Sixteen of 20 (80%) evaluable cases had MGMT-promoter methylation; all 16 were free from progression at 6 months. In conclusion, the rate of progression of 10% during pre-RT temozolomide chemotherapy for newly diagnosed AO and MAO compared favorably with prior experience with pre-RT PCV chemotherapy (20% in RTOG 9402). The toxicity of the dose-intense pre-RT regimen used in this study may warrant evaluation of other, less intense dosing strategies. Future studies will need to prospectively stratify patients according to the presence of deletions of chromosomes 1p and 19q. Neuro-Oncology 11, 167-175, 2009 (Posted to Neuro- Oncology [serial online], Doc. D08-00104, September 8, 2008. URL http://neuro-oncology.dukejournals.org;

AB - The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA). Preirradiation temozolomide (150 mg/m2/day) was given on a 7-day-on/7-day-off schedule for up to six cycles. The primary end point was the response rate during the 6-month, pre-RT chemotherapy. Tumor tissue was analyzed for the presence of chromosomal deletions on 1p and 19q and for MGMT-promoter methylation. Forty-two patients were enrolled; 39 were eligible. The objective response rate was 32% (6% [complete response, CR], 26% [partial response PR]), and the rate of progression during pre-RT chemotherapy was 10%. The worst nonhematological toxicity was grade 4 in three patients (8%). Twenty-two patients completed concurrent chemotherapy and RT. There were no grade 4 nonhematological toxicities during the concurrent chemotherapy and RT. Seventeen of 28 (60.7%) evaluable cases had codeletion of 1p/19q; all 17 were free from progression at 6 months. Sixteen of 20 (80%) evaluable cases had MGMT-promoter methylation; all 16 were free from progression at 6 months. In conclusion, the rate of progression of 10% during pre-RT temozolomide chemotherapy for newly diagnosed AO and MAO compared favorably with prior experience with pre-RT PCV chemotherapy (20% in RTOG 9402). The toxicity of the dose-intense pre-RT regimen used in this study may warrant evaluation of other, less intense dosing strategies. Future studies will need to prospectively stratify patients according to the presence of deletions of chromosomes 1p and 19q. Neuro-Oncology 11, 167-175, 2009 (Posted to Neuro- Oncology [serial online], Doc. D08-00104, September 8, 2008. URL http://neuro-oncology.dukejournals.org;

UR - http://www.scopus.com/inward/record.url?scp=65949101643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65949101643&partnerID=8YFLogxK

U2 - 10.1215/15228517-2008-073

DO - 10.1215/15228517-2008-073

M3 - Article

C2 - 18779504

AN - SCOPUS:65949101643

VL - 11

SP - 167

EP - 175

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 2

ER -